Insilico Medicine
insilico-medicine-78d8aff0·2 events·first seen 16d agoAliases: Insilico Medicine
Co-occurring entities
More like this (12)
Recent events (2)
Eli Lilly Commits Up to $2.75 Billion to Insilico Medicine for AI-Driven Drug Discovery
Eli Lilly agreed to pay up to $2.75 billion to Insilico Medicine, a Hong Kong biotech using generative AI across its drug-discovery pipeline, with an initial $115 million for exclusive rights to undisclosed pre-clinical drug candidates. Insilico's platform uses PandaOmics for target identification and Chemistry42 for molecule design, reducing the time from target identification to preclinical candidates from 5-6 years to roughly 18 months and screening far fewer compounds than conventional methods. The deal is the third between the companies and follows positive Phase 2a results for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis. No AI-discovered drug has yet received regulatory approval, and the key open question is whether AI-accelerated compounds will show higher clinical trial success rates than traditionally developed drugs.
Data Points: Hackers Break Into Claude Mythos; OpenAI Launches Cybersecurity Rival; Maine Data Center Moratorium; McClatchy AI Backlash
A small group of unauthorized users gained access to Anthropic's restricted Claude Mythos cybersecurity model via Discord coordination and insider knowledge, raising questions about securing high-risk AI systems. OpenAI responded to the competitive landscape by launching GPT-5.4-Cyber, a vetted-access model for defensive cybersecurity tasks. Maine passed the first U.S. state moratorium on large AI data centers over 20MW, pending the governor's signature. McClatchy's deployment of a Claude-powered content scaling agent triggered newsroom backlash over attribution, consent, and AI disclosure standards.